... Targeted Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) ...
NSCLC Targeted Therapy: 8 Facts
... Targeted Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) ...
... therapies for NSCLC include: Vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab (Avastin) and ramucirumab (Cyramza) KRAS inhibitors, such as adagrasib (Krazati) and sotorasib (Lumakras) Epidermal growth factor receptor (EGFR) inhibitors, such as afatinib (Gilotrif), dacomitinib (Vizimpro), erlotinib, gefitinib (Iressa), lazertinib (Lazcluze ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... therapies for NSCLC include: Vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab (Avastin) and ramucirumab (Cyramza) KRAS inhibitors, such as adagrasib (Krazati) and sotorasib (Lumakras) Epidermal growth factor receptor (EGFR) inhibitors, such as afatinib (Gilotrif), dacomitinib (Vizimpro), erlotinib, gefitinib (Iressa), lazertinib (Lazcluze ...
... A second approval followed for amivantamab-vmjw combined with lazertinib (Lazcluze) to treat locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.These new treatment options offer hope for people whose cancer hasn’t responded to earlier EGFR therapies.Read more about EGFR-positive lung cancer.5. ...
Biomarkers for Lung Cancer: 12 Things To Know
... A second approval followed for amivantamab-vmjw combined with lazertinib (Lazcluze) to treat locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.These new treatment options offer hope for people whose cancer hasn’t responded to earlier EGFR therapies.Read more about EGFR-positive lung cancer.5. ...
... Small molecular inhibitors have been developed to target EGFR mutations, such as: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Erlotinib Gefitinib Lazertinib (Lazcluze) Necitumumab (Portrazza) Sunvozertinib (Zegfrovy) These small molecular inhibitors can shrink tumors for an extended period. ...
Lung Cancer Treatment Options
... Small molecular inhibitors have been developed to target EGFR mutations, such as: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Erlotinib Gefitinib Lazertinib (Lazcluze) Necitumumab (Portrazza) Sunvozertinib (Zegfrovy) These small molecular inhibitors can shrink tumors for an extended period. ...
... Food and Drug Administration (FDA) approved lazertinib (Lazcluze) in combination with amivantamab-vmjw for NSCLC with certain EGFR mutations.In 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy), a kinase inhibitor used to treat NSCLC with EGFR exon 20 insertion mutations in people whose cancer has progressed after platinum-based ...
How Does Targeted Therapy for Lung Cancer Work?
... Food and Drug Administration (FDA) approved lazertinib (Lazcluze) in combination with amivantamab-vmjw for NSCLC with certain EGFR mutations.In 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy), a kinase inhibitor used to treat NSCLC with EGFR exon 20 insertion mutations in people whose cancer has progressed after platinum-based ...
... Some of the latest ones include: Ensartinib (Ensacove) — Approved in 2024 for people with ALK-positive advanced or metastatic NSCLC Lazertinib (Lazcluze) — Approved in 2024 for people with advanced or metastatic NSCLC with certain EGFR mutations Taletrectinib (Ibtrozi) — Approved in 2025 for adults with locally advanced or metastatic NSCLC that tests ...
NSCLC: Advances in Diagnosis, Staging, and Metastatic Therapies (VIDEO)
... Some of the latest ones include: Ensartinib (Ensacove) — Approved in 2024 for people with ALK-positive advanced or metastatic NSCLC Lazertinib (Lazcluze) — Approved in 2024 for people with advanced or metastatic NSCLC with certain EGFR mutations Taletrectinib (Ibtrozi) — Approved in 2025 for adults with locally advanced or metastatic NSCLC that tests ...
Join
